logo

Stoke Therapeutics Inc (STOK)



Trade STOK now with
  Date
  Headline
8/25/2022 7:45:37 AM Stoke Therapeutics Enrolls First Patient In Natural History Study Of People Living With Autosomal Dominant Optic Atrophy
8/8/2022 7:56:05 AM Stoke Therapeutics Q2 Net Loss $24.7 Mln Or $0.63/shr Vs Loss $22.0 Mln Or $0.60/shr Prior Year
5/10/2022 7:14:51 AM Stoke Therapeutics Q1 Net Loss $24.6 Mln Or $0.66/shr Vs Loss $16.8 Mln Or $0.46/shr Priro Year
1/10/2022 7:10:58 AM Acadia, Stoke Therapeutics To Pursue Multiple RNA-based Treatments For Severe &Rare Genetic Neurodevelopmental Diseases
12/3/2021 10:05:18 AM Stoke Therapeutics Presents Data From Phase 1/2a MONARCH Study Of STK-001 In Children &Adolescents With Dravet Syndrome
11/8/2021 7:21:33 AM Stoke Therapeutics Q3 Net Loss $22.6 Mln Or $0.61/Shr Vs Loss $13.7 Mln Or $0.41/Shr Last Year
9/21/2021 7:07:26 AM Stoke Announces Positive Data From Phase 1/2a MONARCH Study Of STK-001 In Children And Adolescents With Dravet Syndrome
8/10/2021 7:06:00 AM Stoke Therapeutics Q2 Net Loss $22.0 Mln Or $0.60/shr Vs. Loss $13.0 Mln Or $0.39/shr Prior Year
5/10/2021 7:45:00 AM Stoke Therapeutics Q1 Net Loss $16.8 Mln Or $0.46 Per Share
3/30/2021 7:43:41 AM Stoke Therapeutics Announces MHRA Authorization To Begin Phase 1/2a Clinical Trial Of STK-001 For Dravet Syndrome In UK